Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JT to market CORECTIM in Japan to treat atopic dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"$22.0 million","newsHeadline":"BioCryst Submits Japanese NDA for Oral, Once Daily Berotralstat","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"$11.5 million","newsHeadline":"Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","amount":"$69.5 million","upfrontCash":"$11.5 million","newsHeadline":"Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical for VP-102","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO\u2122 (berotralstat) for Prophylactic Treatment of Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Nogra Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Torii Has Entered Into a License Agreement with Nogra Pharma Limited to Develop & Commercialize NAC-GED-0507 in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Torii Pharmaceutical

    Menu

    Torii Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Torii Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Torii Has Entered Into a License Agreement with Nogra Pharma Limited to Develop & Commercialize NAC-GED-0507 in Japan

              Details:

              Under the agreement, Torii Pharmaceuticals will gain exclusive development and commercialisation rights for NAC-GED-0507 in Japan for the treatment of acne vulgaris. NAC-GED-0507 is an IP protected, Phase III-ready, small molecule selective modulator of the PPARγ.

              Lead Product(s): NAC-GED-0507

              Therapeutic Area: Dermatology Product Name: NAC-GED-0507

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Nogra Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Torii Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan

              Details:

              VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration.

              Lead Product(s): Cantharidin

              Therapeutic Area: Infections and Infectious Diseases Product Name: Ycanth

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Verrica Pharmaceuticals

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Torii Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary Angioedema

              Details:

              Oral, once-daily ORLADEYO was approved in Japan in January 2021 for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

              Lead Product(s): Berotralstat

              Therapeutic Area: Genetic Disease Product Name: Orladeyo

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: BioCryst Pharmaceuticals

              Deal Size: $15.0 million Upfront Cash: Undisclosed

              Deal Type: Collaboration April 14, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Torii Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical for VP-102

              Details:

              Verricaʼs lead product candidate, VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration.

              Lead Product(s): Cantharidin

              Therapeutic Area: Infections and Infectious Diseases Product Name: Ycanth

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Verrica Pharmaceuticals

              Deal Size: $69.5 million Upfront Cash: $11.5 million

              Deal Type: Licensing Agreement March 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Torii Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan

              Details:

              The agreement grants Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102.

              Lead Product(s): Cantharidin

              Therapeutic Area: Infections and Infectious Diseases Product Name: VP-102

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Verrica Pharmaceuticals

              Deal Size: $70.0 million Upfront Cash: $11.5 million

              Deal Type: Agreement August 05, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Torii Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioCryst Submits Japanese NDA for Oral, Once Daily Berotralstat

              Details:

              Torii Pharmaceutical will pay tiered royalties of up to 40 percent of Japanese net sales of berotralstat to BioCryst upon receipt of a reimbursement price approval NHI Japan.

              Lead Product(s): Berotralstat

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: BioCryst Pharmaceuticals

              Deal Size: $42.0 million Upfront Cash: $22.0 million

              Deal Type: Agreement February 03, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Torii Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              JT to market CORECTIM in Japan to treat atopic dermatitis

              Details:

              Under the terms of the agreement on October 2016nbetween JT and Torii, the drugs will be sold exclusively by Torii in Japan, following itsninclusion in the National Health Insurance (NHI) price list.

              Lead Product(s): Delgocitinib

              Therapeutic Area: Dermatology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Japan Tobacco Inc

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 15, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY